{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:54:32Z","timestamp":1777424072415,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81725003"],"award-info":[{"award-number":["81725003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31671181"],"award-info":[{"award-number":["31671181"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91739303"],"award-info":[{"award-number":["91739303"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Summit & Plateau Discipline Developing Projects"},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["18ZR1432800"],"award-info":[{"award-number":["18ZR1432800"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010032","name":"Shanghai Municipal Commission of Health and Family Planning","doi-asserted-by":"publisher","award":["201740176"],"award-info":[{"award-number":["201740176"]}],"id":[{"id":"10.13039\/501100010032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.atherosclerosis.2018.05.005","type":"journal-article","created":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T01:23:54Z","timestamp":1525483434000},"page":"199-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Myeloid peroxisome proliferator-activated receptor gamma deficiency aggravates myocardial infarction in mice"],"prefix":"10.1016","volume":"274","author":[{"given":"Zhu-Xia","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Zhen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin-Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Nan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Yong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Hui","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Min","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Zhong","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib1","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/eurheartj\/ehv453","article-title":"Innate immune cells in ischaemic heart disease: does myocardial infarction beget myocardial infarction?","volume":"37","author":"Nahrendorf","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib2","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/CIRCRESAHA.111.300484","article-title":"Endoscopic time-lapse imaging of immune cells in infarcted mouse hearts","volume":"112","author":"Jung","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib3","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1161\/CIRCRESAHA.114.303204","article-title":"Ly-6Chigh monocytes depend on Nr4a1 to balance both inflammatory and reparative phases in the infarcted myocardium","volume":"114","author":"Hilgendorf","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2015.00107","article-title":"Myocardial infarction: a critical role of macrophages in cardiac remodeling","volume":"6","author":"Weinberger","year":"2015","journal-title":"Front. Physiol."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib5","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1161\/CIRCRESAHA.116.309001","article-title":"Proliferation and recruitment contribute to myocardial macrophage expansion in chronic heart failure","volume":"119","author":"Sager","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib6","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1084\/jem.20070885","article-title":"The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions","volume":"204","author":"Nahrendorf","year":"2007","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jacc.2009.04.021","article-title":"Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction","volume":"54","author":"Tsujioka","year":"2009","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jjcc.2010.10.003","article-title":"Elevated peripheral blood mononuclear cell count is an independent predictor of left ventricular remodeling in patients with acute myocardial infarction","volume":"57","author":"Aoki","year":"2010","journal-title":"J.\u00a0Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib9","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.jacc.2009.08.089","article-title":"Impaired infarct healing in atherosclerotic mice with Ly-6Chi monocytosis","volume":"55","author":"Panizzi","year":"2010","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib10","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib11","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ahj.2013.05.004","article-title":"Results of a reevaluation of cardiovascular outcomes in the RECORD trial","volume":"166","author":"Mahaffey","year":"2013","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40261-013-0106-9","article-title":"Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights","volume":"33","author":"Vallarino","year":"2013","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib14","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib15","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jacc.2006.12.048","article-title":"The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study","volume":"49","author":"Erdmann","year":"2007","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010693.pub2","article-title":"Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack","author":"Liu","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/hep.21963","article-title":"Peroxisome proliferator-activated receptor-\u03b3 protects against hepatic ischemia\/reperfusion injury in mice","volume":"47","author":"Kuboki","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib18","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1172\/JCI28859","article-title":"Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality","volume":"117","author":"Duan","year":"2007","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib19","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1161\/CIRCULATIONAHA.108.815803","article-title":"Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-\u03b3 deletion leads to hypotension","volume":"119","author":"Chang","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib20","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/cvr\/cvs362","article-title":"VSMC-specific PPAR\u03b3 knockout aggravates angiotensin II (Ang II)-induced vascular remodelling","volume":"97","author":"Marchesi","year":"2012","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib21","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.112.104489","article-title":"Loss of perivascular adipose tissue on peroxisome proliferator\u2013activated receptor-\u03b3 deletion in smooth muscle cells impairs intravascular thermoregulation and enhances atherosclerosis","volume":"126","author":"Chang","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib22","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1161\/CIRCRESAHA.110.219089","article-title":"Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell\u2013specific interaction with PPAR\u03b3","volume":"107","author":"Subramanian","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib23","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/ATVBAHA.110.219006","article-title":"Vascular smooth muscle cell peroxisome proliferator\u2013activated receptor-\u03b3 mediates pioglitazone-reduced vascular lesion formation","volume":"31","author":"Hamblin","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib24","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/ncomms2087","article-title":"The nuclear hormone receptor PPAR\u03b3 counteracts vascular calcification by inhibiting Wnt5a signalling in vascular smooth muscle cells","volume":"3","author":"Woldt","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib25","first-page":"110","article-title":"PPAR gamma in the endothelium regulates metabolic responses to high-fat diet in mice","volume":"119","author":"Kanda","year":"2009","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/ATVBAHA.111.239137","article-title":"Disruption of endothelial peroxisome proliferator-activated receptor gamma accelerates diet-induced atherogenesis in LDL receptor-null mice","volume":"32","author":"Qu","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib27","doi-asserted-by":"crossref","first-page":"H1647","DOI":"10.1152\/ajpheart.00148.2009","article-title":"Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production","volume":"297","author":"Kleinhenz","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib28","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/01.RES.0000179226.34112.6d","article-title":"Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-\u03b3 both induce cardiac hypertrophy in mice","volume":"97","author":"Duan","year":"2005","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib29","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.2337\/db07-0924","article-title":"Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor \u03b3 in cardiac fibrosis","volume":"57","author":"Caglayan","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00395-011-0162-3","article-title":"Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-\u03b3-independent manner","volume":"106","author":"Birnbaum","year":"2011","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib31","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/01.ATV.0000173413.31789.1a","article-title":"Conditional knockout of macrophage PPAR\u03b3 increases atherosclerosis in C57BL\/6 and low-density lipoprotein receptor\u2013deficient mice","volume":"25","author":"Babaev","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib32","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature05894","article-title":"Macrophage-specific PPAR\u03b3 controls alternative activation and improves insulin resistance","volume":"447","author":"Odegaard","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib33","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/path.4548","article-title":"Macrophage PPAR\u03b3 and impaired wound healing in type 2 diabetes","volume":"236","author":"Mirza","year":"2015","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib34","doi-asserted-by":"crossref","first-page":"15712","DOI":"10.1073\/pnas.2536828100","article-title":"Adipose-specific peroxisome proliferator-activated receptor \u03b3 knockout causes insulin resistance in fat and liver but not in muscle","volume":"100","author":"He","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib35","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.cardiores.2003.09.026","article-title":"Pharmacological therapy can increase capillary density in post-infarction remodeled rat hearts","volume":"61","author":"Van Kerckhoven","year":"2004","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib36","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1152\/japplphysiol.00033.2007","article-title":"Myocardial infarct size measurement in the mouse chronic infarction model: comparison of area- and length-based approaches","volume":"102","author":"Takagawa","year":"2007","journal-title":"J.\u00a0Appl. Physiol."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib37","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/CIRCRESAHA.110.223925","article-title":"A\u00a0novel and efficient model of coronary artery ligation and myocardial infarction in the mouse","volume":"107","author":"Gao","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib38","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1074\/jbc.M116.739243","article-title":"Mineralocorticoid receptor deficiency in macrophages inhibits atherosclerosis by affecting foam cell formation and efferocytosis","volume":"292","author":"Shen","year":"2017","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib39","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","article-title":"Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction","volume":"123","author":"Fraccarollo","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib40","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1111\/bph.13029","article-title":"The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges","volume":"172","author":"Cheang","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib41","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cmet.2011.05.009","article-title":"Adiponectin is required for PPAR\u03b3-mediated improvement of endothelial function in diabetic mice","volume":"14","author":"Wong","year":"2011","journal-title":"Cell Metabol."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib42","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1161\/CIRCRESAHA.111.243972","article-title":"Biochemistry, physiology and pathophysiology of NADPH oxidases in the cardiovascular system","volume":"110","author":"Lass\u00e8gue","year":"2012","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib43","doi-asserted-by":"crossref","first-page":"15565","DOI":"10.1073\/pnas.1002178107","article-title":"NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart","volume":"107","author":"Kuroda","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib44","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1161\/HYPERTENSIONAHA.107.101980","article-title":"Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction","volume":"51","author":"Looi","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib45","doi-asserted-by":"crossref","first-page":"7790","DOI":"10.1016\/j.biomaterials.2013.06.051","article-title":"Delivery of Nox2-NADPH oxidase siRNA with polyketal nanoparticles for improving cardiac function following myocardial infarction","volume":"34","author":"Somasuntharam","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib46","doi-asserted-by":"crossref","first-page":"18121","DOI":"10.1073\/pnas.1009700107","article-title":"NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis","volume":"107","author":"Zhang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib47","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1161\/CIRCRESAHA.109.213116","article-title":"Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes","volume":"106","author":"Ago","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib48","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jjcc.2015.07.012","article-title":"Effects of \u03b1-lipoic acid therapy on sympathetic heart innervation in patients with previous experience of transient takotsubo cardiomyopathy","volume":"67","author":"Marfella","year":"2016","journal-title":"J.\u00a0Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib49","doi-asserted-by":"crossref","first-page":"6712","DOI":"10.1073\/pnas.1031789100","article-title":"PPAR\u03b3 and PPAR\u03b4 negatively regulate specific subsets of lipopolysaccharide and IFN-\u03b3 target genes in macrophages","volume":"100","author":"Welch","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib50","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1172\/JCI31561","article-title":"Macrophage PPAR\u03b3 is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones","volume":"117","author":"Hevener","year":"2007","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib51","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1126\/science.1230719","article-title":"Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure","volume":"339","author":"Swirski","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib52","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib53","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1016\/j.ijcard.2013.06.053","article-title":"Peri-procedural tight glycemic control during early percutaneous coronary intervention up-regulates endothelial progenitor cell level and differentiation during acute ST-elevation myocardial infarction: effects on myocardial salvage","volume":"168","author":"Marfella","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib54","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2337\/db14-1149","article-title":"Sirtuin 6 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of incretin treatment","volume":"64","author":"Balestrieri","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib55","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1210\/jc.2010-1382","article-title":"Innate immune activity in plaque of patients with untreated and L-thyroxine-treated subclinical hypothyroidism","volume":"96","author":"Marfella","year":"2011","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib56","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-017-1191-y","article-title":"Apoptosis in ischemic heart disease","volume":"15","author":"Teringova","year":"2017","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.atherosclerosis.2018.05.005_bib57","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/j.1463-1326.2009.01097.x","article-title":"The PPAR-gamma agonist rosiglitazone facilitates Akt rephosphorylation and inhibits apoptosis in cardiomyocytes during hypoxia\/reoxygenation","volume":"11","author":"Kilter","year":"2009","journal-title":"Diabetes Obes. Meta"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018302430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018302430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T23:54:11Z","timestamp":1534895651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915018302430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":57,"alternative-id":["S0021915018302430"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.05.005","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myeloid peroxisome proliferator-activated receptor gamma deficiency aggravates myocardial infarction in mice","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}